Abstract
The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
Current Drug Targets
Title: New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets
Volume: 9 Issue: 5
Author(s): Tommaso Stefanelli, Alberto Malesci, Alessandro Repici, Stefania Vetrano and Silvio Danese
Affiliation:
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
Abstract: The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Export Options
About this article
Cite this article as:
Stefanelli Tommaso, Malesci Alberto, Repici Alessandro, Vetrano Stefania and Danese Silvio, New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets, Current Drug Targets 2008; 9 (5) . https://dx.doi.org/10.2174/138945008784221170
DOI https://dx.doi.org/10.2174/138945008784221170 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis
Current Drug Safety Autoantibody Reaction to Myelin Basic Protein by Plasma Parvovirus B19 IgG in MS Patients
Protein & Peptide Letters Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Potassium Channels and Uterine Vascular Adaptation to Pregnancy and Chronic Hypoxia
Current Vascular Pharmacology Antibodies Against Complement System in SLE and their Potential Diagnostic Utility
Current Rheumatology Reviews Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews A New Biomarker with High Outcome Prediction in IgA Nephropathy
Recent Patents on Biomarkers Functions of S100 Proteins
Current Molecular Medicine New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Nuclear Receptor PPARα in the Sleep-wake Cycle Modulation. A Tentative Approach for Treatment of Sleep Disorders
Current Drug Delivery Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry